Loading company…
Theseus Pharmaceuticals developed kinase inhibitors for cancers with treatment-resistant mutations.
Founded in 2017, Theseus Pharmaceuticals researched kinase inhibitors for cancers with drug resistance mutations, including refractory GIST and non-small cell lung cancer. Its pipeline included a KIT inhibitor and an EGFR inhibitor. The company became publicly listed on Nasdaq under ticker THRX in October 2021 and agreed to merge into Concentra, Inc. in December 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in